The core idea behind biomimetic nanomedicine is deceptively simple. Nanoparticles, whether synthetic or natural in origin, are coated with materials derived from living cells, such as membranes from platelets, macrophages, neutrophils, natural killer cells, erythrocytes, or even cancer cells themselves. Alternatively, they can be decorated with naturally derived biomolecules like monoclonal antibodies, viral capsids, and natural proteins, or with synthetic analogues such as targeting peptides and aptamers. This biological disguise confers several decisive advantages. The particles circulate in the bloodstream for longer periods, evade recognition by the reticuloendothelial system, accumulate preferentially in tumor tissue, and provoke far fewer unwanted immune reactions than conventional nanocarriers. In effect, the drug carrier stops looking like a foreign invader and starts looking like something the body already tolerates.

The review grounds this technological optimism in a detailed account of colon cancer biology. The disease typically unfolds over ten to twenty years through the well-characterized adenoma-carcinoma sequence. Loss of the APC tumor suppressor gene triggers uncontrolled proliferation and the formation of benign polyps. Subsequent activation of the KRAS oncogene drives growth into a large adenoma, while deletion of the DCC gene, involved in cell adhesion and apoptosis, permits abnormal cells to invade neighboring tissue. The final transformation comes with loss of p53, the guardian of DNA repair and programmed cell death, after which cells accumulate further mutations, breach the basement membrane, and metastasize to organs such as the liver and lungs. Understanding this stepwise molecular progression, the authors argue, is essential for designing nanocarriers that intervene at the right biological moment.

Among the most striking platforms described in the review are cell membrane-coated nanoparticles. By wrapping a synthetic drug-loaded core in the membrane of a red blood cell, platelet, or immune cell, researchers inherit the surface chemistry of that cell, including its complement-regulating proteins and adhesion molecules. Preclinical work highlighted in the review illustrates the potential vividly. In a mouse model of inflammation-driven colorectal cancer, biomimetic PLGA nanoparticles coated with red blood cell membranes and loaded with the enzyme shikimokinase produced stable body weights, reduced disease activity scores, longer colons, fewer tumor nodules, restored crypt architecture on histology, and enhanced apoptosis of tumor cells as measured by TUNEL staining. The membrane-coated formulations outperformed their uncoated counterparts across every endpoint, a result the authors present as evidence that biomimicry is not merely cosmetic but functionally therapeutic.

Exosome-based carriers represent a second major pillar. Exosomes are naturally occurring extracellular vesicles that cells use to communicate, and their innate ability to cross biological barriers makes them attractive delivery vehicles. Yet the review is candid about their limitations. Isolation methods such as ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture yield heterogeneous populations with inconsistent purity, undermining reproducibility. Cargo loading through passive incubation, electroporation, or chemical transfection still suffers from low encapsulation rates and rapid release. Once injected, exosomes face rapid clearance, aggregation, and degradation in circulation. Engineering strategies, including genetic modification of donor cells to display tumor-targeting peptides on the exosome surface, offer improved intrinsic targeting, while surface functionalization provides greater flexibility and scalability. The authors call for systematic studies of drug loading, release kinetics, and therapeutic efficacy to establish the standardized protocols that clinical translation will demand.

Inorganic and metal-based nanoparticles form a third, chemically diverse family. Gold nanoparticles, ranging from one to one thousand nanometers and available in spherical, rod, star, and cage morphologies, can convert near-infrared light into heat, making them potent agents for photothermal therapy. In one study cited in the review, photostable gold nanoparticles averaging roughly 180 nanometers were absorbed by colon cancer cells, as confirmed by increased cellular granularity, and produced a dramatic drop in cell viability after treatment. Silver nanoparticles take a different route, generating reactive oxygen species that induce oxidative stress, mitochondrial damage, membrane rupture, and apoptosis. Research on the SW480 colon cancer cell line showed that silver nanoparticles functionalized with glutamine and conjugated with thiosemicarbazide triggered apoptosis through notable caspase activation and downregulation of the HULC long non-coding RNA and the PPFIA4 oncogene. Silver nanoparticles can also enhance the tumor accumulation of conventional drugs like doxorubicin while reducing toxicity to healthy tissue, and their strong light-scattering properties make them useful as contrast agents in dark-field microscopy and surface-enhanced Raman scattering.

The review also catalogs the contributions of softer organic platforms. Dendrimers, tree-like branched macromolecules whose size and surface chemistry are controlled generation by generation, can be loaded with drugs in their interior cavities or conjugated to their periphery. Fourth-generation PAMAM dendrimers carrying capecitabine shrank tumors in mouse models with fewer effects on blood and liver than the free drug, while pegylated PAMAM dendrimers decorated with AS1411 anti-nucleolin aptamers showed heightened sensitivity against HT29 and C26 colorectal cancer cells and efficacy in tumor-bearing mice. A fifth-generation L-lysine dendrimer modified with polyoxazoline improved the therapeutic index of SN-38, the active metabolite of irinotecan, by controlling drug release and extending circulation time. Liposomes, the oldest clinical nanomedicine platform, continue to evolve: FDA-approved formulations such as Doxil and DaunoXome established the field in the 1990s, and temperature-sensitive liposomal doxorubicin, known as Thermodox, delivered twenty-five times more drug to cancer cells than standard intravenous delivery in preclinical testing for colorectal liver metastases.

Carbon nanotubes and quantum dots round out the arsenal. Carbon nanotubes, cylindrical rolls of hexagonally bonded carbon atoms a few nanometers in diameter, penetrate plasma membranes readily thanks to their needle-like shape and vast surface area. Combining single-walled carbon nanotubes with the TRAIL protein increased the death rate in colorectal cancer cell lines roughly tenfold, and carboxylic acid functionalization exploits the acidic lysosomal environment of cancer cells, around pH 5.5 versus 7.4 in healthy tissue, to trigger pH-dependent drug release. Quantum dots, semiconductor particles smaller than ten nanometers, offer exceptional fluorescence and photochemical stability for bioimaging, and carbon quantum dots are emerging as diagnostic and therapeutic tools in their own right. The review notes that colon cancers frequently overexpress placenta-specific protein 1, providing a molecular anchor for targeted nanoparticle binding.

The translational picture is genuinely encouraging but far from settled. The review catalogs a growing roster of clinical trials involving nanotechnology in colon and gastrointestinal cancers, including studies of cetuximab-loaded nanoparticles, liposomal irinotecan combined with FOLFIRI and bevacizumab, liposomal mitomycin-C with capecitabine, and nanoliposomal irinotecan paired with TAS-102. Yet the authors are clear that major bottlenecks remain: scalable manufacturing, batch-to-batch reproducibility, and demanding regulatory pathways under FDA and EMA frameworks. Their proposed solutions include cost-effective microfluidic production, automated bioreactors, comprehensive protocols for exosome isolation and nanoparticle characterization, and early harmonization with regulatory safety and quality standards. Looking forward, they envision theranostic platforms that merge diagnosis and treatment in a single particle, biomimetic carriers that ferry gene-editing tools alongside chemotherapy, nanomaterials engineered to reprogram the tumor microenvironment, and the encapsulation of plant-derived phytochemicals to overcome their poor solubility and low bioavailability. If interdisciplinary collaboration can close the gap between laboratory proof-of-concept and clinical practice, the authors conclude, biomimetic nanomaterials could move colon cancer therapy decisively closer to being safer, more effective, and personally tailored.

Subject of Research: Biomimetic nanomaterials for targeted drug delivery in colon cancer

Article Title: Advances in biomimetic nanomaterials for targeted drug delivery in colon cancer

Article References: Dharme, K. K., Jain, P., Verma, G., & Uddin, A. (2026). Advances in biomimetic nanomaterials for targeted drug delivery in colon cancer. Holistic Integrative Oncology, 5(1), Article 58. https://doi.org/10.1007/s44178-026-00279-4

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00279-4

Keywords: colon cancer, biomimetic nanoparticles, drug delivery, exosomes, cell membrane coating, gold nanoparticles, silver nanoparticles, dendrimers, liposomes, carbon nanotubes, quantum dots, nanomedicine

Whole-genome doubling (WGD), a phenomenon frequently observed in cancer cells, involves the duplication of an entire set of chromosomes, resulting in cells harboring twice the normal chromosomal content. This event is prevalent in roughly 37% of primary solid tumors and even more so in metastatic tumors, where it is detected in up to 56% of cases. Historically, WGD has been associated with poor prognosis, increased genomic instability, and treatment resistance, but the precise biological underpinnings remained elusive.

The latest research provides compelling evidence that WGD does far more than merely augment genomic content; it profoundly alters the interplay between tumor cells and the host immune system. Initially, genome doubling paradoxically enhances tumor cell visibility by increasing immune system recognition; however, this visibility prompts an adaptive response in the cancer cells aimed at achieving immune escape. Dr. Pierre Foidart, a leading oncologist and corresponding author, explains that cancer cells, after this initial heightened immune exposure, swiftly evolve mechanisms to conceal themselves from cytotoxic immune responses.

Central to immune recognition is the presentation of antigenic peptides on the surface of tumor cells via the major histocompatibility complex class I (MHC-I). This complex acts as a crucial “display window,” enabling cytotoxic CD8+ T lymphocytes to identify and target aberrant cells. The innate immune system complements this surveillance by producing interferon-gamma (IFN-γ), a cytokine that upregulates MHC-I expression and bolsters antigen presentation. This dynamic interplay establishes a positive feedback loop: activated CD8+ T cells further secrete IFN-γ, amplifying immune responses and enhancing tumor cell elimination.

Intriguingly, the study reveals that tumor cells undergoing whole-genome doubling eventually suppress the expression of genes encoding MHC-I molecules. This suppression results in a marked reduction of antigen presentation on the tumor cell surface, effectively rendering these cells invisible to CD8+ T lymphocytes. The cells also demonstrate an impaired response to IFN-γ signaling, breaking the positive feedback loop essential for effective immune-mediated clearance. Consequently, cytotoxic T cells fail to recognize and attack these genome-doubled tumor cells, allowing cancer proliferation despite immune presence.

Notably, this immunoevasive phenotype is governed not by genetic mutations but through epigenetic modifications—a suite of reversible molecular changes regulating gene expression without altering the underlying DNA sequence. Metabolic reprogramming in these WGD-positive cells leads to enhanced activity of the Polycomb Repressive Complex 2 (PRC2), a key epigenetic silencer. PRC2 mediates trimethylation of histone H3 at lysine 27 (H3K27me3), a mark associated with gene repression that effectively silences transcriptional regulators critical for antigen presentation.

Dr. Kornélia Polyak of Dana-Farber Cancer Institute highlights the therapeutic potential of targeting these epigenetic pathways: “By pharmacologically inhibiting the PRC2 complex, we can partially reverse the silencing of antigen presentation genes, restoring the immune system’s ability to detect and eliminate WGD-positive tumor cells.” This approach not only enhances immune recognition but also selectively hinders the growth of genome-doubled tumors, offering a dual therapeutic advantage.

The clinical implications of these findings are profound. Whole-genome doubling could serve as a highly informative biomarker, guiding oncologists in stratifying patients and tailoring treatments that combine epigenetic inhibitors with immunotherapeutic agents. This personalized medicine strategy promises to overcome the current limitations of immune checkpoint therapies that fail in tumors adept at immune evasion through antigen presentation loss.

However, several challenges remain before these insights translate into clinical practice. Whole-genome sequencing, the primary method for detecting WGD, is costly and not readily available in routine oncology settings. Addressing this, Dr. Foidart and collaborators are developing novel, accessible methodologies to detect genome doubling in tumors, facilitating widespread clinical adoption and patient benefit.

Beyond breast cancer, the phenomenon of WGD and its associated epigenetic immune evasion may extend to multiple solid tumor types. Understanding the molecular basis of this mechanism across diverse cancers could revolutionize how clinicians predict treatment response and develop combinatorial therapeutic regimens optimized for specific tumor genomic and epigenetic landscapes.

Moreover, the reversible nature of epigenetic modifications offers hope for durable treatment efficacy while potentially minimizing adverse effects commonly associated with irreversible genetic alterations. This reversibility imbues cancer therapy with a new degree of control, as drugs can modulate gene expression dynamically in response to therapeutic needs, improving long-term patient outcomes.

Future research will undoubtedly focus on refining pharmacological inhibitors of epigenetic regulators like PRC2, identifying biomarkers predictive of treatment response, and conducting clinical trials that merge epigenetic therapy with cutting-edge immunotherapies. Such multidisciplinary approaches are expected to unlock unprecedented strategies in cancer treatment, transforming grim prognoses into manageable or even curable conditions.

In summary, the identification of an epigenetic mechanism by which whole-genome doubling drives immune evasion marks a paradigm shift in our understanding of tumor-immune interactions. This research elevates the concept that cancer progression is not solely rooted in genetic mutations but also intricately linked to reversible epigenetic adaptations that alter cellular identity and immune visibility. Harnessing these insights through targeted therapies holds promise to significantly enhance the efficacy of cancer immunotherapy and improve survival rates for patients worldwide.

Subject of Research: Whole-genome doubling and its role in tumor immune evasion via epigenetic silencing of antigen presentation.

Article Title: Whole-genome doubling drives immune evasion by silencing antigen presentation

News Publication Date: 7-May-2026

Web References:
– DOI link: http://dx.doi.org/10.1016/j.ccell.2026.04.007
– University of Liège: http://www.uliege.be
– Dana-Farber Cancer Institute: https://www.dana-farber.org/

References:
Foidart et al., Whole-genome doubling drives immune evasion by silencing antigen presentation, Cancer Cell, Elsevier, May 2026

Image Credits: Foidart et al., Whole-genome doubling drives immune evasion by silencing antigen presentation, Cancer Cell, Elsevier, May 2026

Keywords: Whole-genome doubling, immune evasion, cancer immunotherapy, epigenetics, PRC2, antigen presentation, MHC-I, interferon gamma, CD8+ T lymphocytes, breast cancer, tumor biology, epigenetic therapy

At the heart of this exploration lies the compelling intersection of natural products and targeted cancer therapies, a convergence that offers a beacon of hope for overcoming resistance and enhancing treatment efficacy. Curcumin, long celebrated for its anti-inflammatory and antioxidant properties, has now been repositioned in the oncology landscape due to its potential to modulate numerous signaling pathways integral to tumor progression and survival. Meanwhile, PARP inhibitors have cemented their place in cancer therapy by exploiting synthetic lethality, particularly in tumors deficient in homologous recombination repair, such as BRCA-mutated cancers.

The review meticulously synthesizes data derived from network pharmacology—a systems biology approach that maps the intricate interactions between drug molecules and biological targets. This methodology allows for a comprehensive understanding of how curcumin and PARP inhibitors orchestrate a concerted attack on cancer cells, contributing to enhanced cytotoxicity. Network pharmacology highlights curcumin’s capacity to modulate key nodes within cancer-related pathways, including NF-kB, STAT3, and PI3K/Akt/mTOR, thereby amplifying the DNA damage inflicted by PARP inhibition.

A salient point emerging from this report is curcumin’s role in sensitizing resistant cancer cells to PARP inhibitors. Resistance remains a formidable obstacle in clinical oncology, often limiting the long-term success of targeted therapies. By downregulating resistance-related genes and proteins, curcumin appears to restore or heighten the vulnerability of tumor cells to PARP inhibition, suggesting a potent adjunctive role that transcends mere additive effects.

Moreover, the dual action of curcumin in attenuating inflammation and oxidative stress presents a valuable therapeutic advantage, as these microenvironmental factors notoriously contribute to cancer progression and therapeutic resistance. This multidimensional effect not only facilitates tumor suppression but may also improve patient outcomes by reducing systemic toxicity, a frequent challenge with conventional chemotherapeutics.

At a molecular level, the review elucidates how curcumin’s epigenetic modulation complements the DNA repair blockade initiated by PARP inhibitors. Epigenetic changes, including histone modification and DNA methylation alterations, are pivotal in gene expression regulation within cancer cells. Curcumin’s influence on these processes may disrupt oncogenic transcriptional programs, thereby synergizing with PARP inhibitors to induce apoptotic cascades more effectively.

This synergistic potential is not confined to a single cancer type. The network pharmacology framework reveals promising implications across diverse malignancies, including breast, ovarian, prostate, and pancreatic cancers. Each of these cancers exhibits unique molecular vulnerabilities that curcumin and PARP inhibitors can collectively exploit, underscoring the versatility and broad applicability of this combination therapy.

Translational research is primed for breakthrough clinical trials, propelled by these insights. However, challenges persist—most notably, curcumin’s notoriously poor bioavailability. The review highlights advances in drug delivery systems, such as nanoparticle encapsulation and liposomal formulations, which enhance curcumin’s pharmacokinetic profile and maximize its therapeutic impact when combined with PARP inhibitors.

The review also touches on the evolving landscape of precision medicine, emphasizing that the identification of predictive biomarkers will be crucial for patient stratification. By selecting individuals most likely to benefit, specifically those with identifiable DNA repair deficiencies and inflammatory signatures, clinicians can optimize dosing regimens for maximized synergy and minimized adverse effects.

Importantly, safety profiles of both compounds were examined, with curcumin demonstrating a favorable toxicity spectrum alongside potential hepatoprotective effects. This aligns with the growing trend toward integrating natural compounds in cancer therapy paradigms to reduce the collateral damage often seen with aggressive chemotherapy.

From a mechanistic viewpoint, the interplay between curcumin’s antioxidative defense modulation and PARP inhibitors’ induction of DNA damage creates a paradox that, intriguingly, enhances selective tumor cell killing while sparing healthy cells. This selective toxicity phenomenon is a cornerstone of emerging therapeutic strategies and reflects an advanced understanding of cancer biology shaped by network pharmacological insights.

The implications of this research resonate beyond oncology, hinting at broader applications where combined modulation of repair pathways and the tumor microenvironment could prove transformative. Chronic diseases characterized by aberrant DNA repair and inflammation might also benefit from such therapeutic synergies, expanding the clinical horizon for this curcumin-PARP inhibitor collaboration.

As the oncology community digests these findings, a clarion call arises for multidisciplinary efforts encompassing molecular biology, pharmacology, and clinical sciences. The integration of traditional medicine compounds with cutting-edge targeted therapies could redefine the treatment landscape and inspire novel drug development pipelines informed by system-level analyses.

In conclusion, the meticulous synthesis offered by Khanehzar and colleagues illuminates a golden touch—a phrase poetic yet apt—for the curcumin and PARP inhibitor alliance. This alliance, supported by robust network pharmacology evidence, promises not only to augment therapeutic outcomes but also to provide a blueprint for harnessing natural compounds alongside molecular precision drugs in the relentless battle against cancer.

As ongoing and future studies refine dosing, delivery, and patient selection, the prospect of translating this synergy into clinical practice grows ever more tangible. Ultimately, embracing such innovative combinations may herald a new chapter in oncology, where the convergence of nature’s bounty and molecular science yields unprecedented hope for patients worldwide.

Subject of Research: The synergistic interaction between curcumin and PARP inhibitors in cancer therapy and their mechanistic pathways analyzed through network pharmacology.

Article Title: The golden touch: a comprehensive network pharmacology-guided review of synergy between curcumin and PARP inhibitors.

Article References:
Khanehzar, E., Shams, F. & Jafari, A. The golden touch: a comprehensive network pharmacology-guided review of synergy between curcumin and PARP inhibitors. Med Oncol 43, 20 (2026). https://doi.org/10.1007/s12032-025-03140-2

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03140-2

Iron, an essential metal ion pivotal to numerous cellular processes, plays a dual role in cancer biology. While it supports cell growth and proliferation through its involvement in DNA synthesis and metabolic activity, excess iron can catalyze the production of reactive oxygen species (ROS), leading to oxidative stress and cell damage. The intricate regulation of intracellular iron is mediated by Iron Regulatory Proteins (IRPs), with IRP2 emerging as a key modulator in maintaining iron homeostasis. The study highlights that breast cancer cells exploit IRP2 to sustain their iron metabolism pathways, fostering resilience against therapeutic interventions such as radiation.

Radiotherapy remains a cornerstone in breast cancer management; however, intrinsic and acquired radioresistance often diminishes its efficacy, leaving many patients vulnerable to recurrence and metastasis. The newly elucidated role of IRP2 in this resistance mechanism stems from its regulation of iron availability, which in turn affects mitochondrial function—the powerhouse of the cell intimately linked to apoptotic pathways and oxidative stress response. By perturbing IRP2 function, researchers have demonstrated a critical vulnerability in cancer cells, where impaired iron metabolism compromises mitochondrial integrity, thereby sensitizing cells to radiation-induced damage.

Utilizing a combination of genetic knockdown models and pharmacological inhibitors specific to IRP2, the study delineates a clear causal relationship between IRP2 inhibition and heightened radiosensitivity in various breast cancer cell lines. These manipulations led to pronounced mitochondrial dysfunction, characterized by diminished membrane potential, disrupted electron transport chain activity, and elevated mitochondrial ROS production. This mitochondrial collapse effectively undermines cellular defenses against radiation, culminating in increased DNA damage, apoptotic signaling, and ultimately, cell death.

The mechanistic exploration further delves into iron’s pivotal role in the mitochondrial electron transport chain, particularly its incorporation in iron-sulfur clusters essential for electron transfer. IRP2 disruption results in altered expression of key iron metabolism genes, reducing mitochondrial iron import and impairing electron transport chain function. Consequently, the generated ROS surges beyond the neutralizing capacity of cellular antioxidants, pushing cancer cells toward irreversible oxidative damage when exposed to ionizing radiation.

A compelling facet of this research lies in its translational applicability. By pinpointing IRP2 as a novel target, the study paves the way for the development of adjunct therapies that can be co-administered with radiotherapy. Such combined modalities hold the potential to lower radiation doses required to achieve tumor control, thereby mitigating collateral damage to healthy tissues and minimizing side effects commonly associated with radiation treatment.

Moreover, the investigation broadens the perspective on mitochondrial dynamics in cancer therapy resistance. Mitochondria, beyond their conventional metabolic roles, function as central hubs integrating various stress signals. Their susceptibility to iron metabolism perturbations unveils a strategic chokepoint that can be exploited to subvert cancer cell survival mechanisms, bringing mitochondrial modulation to the forefront of oncological research.

Interestingly, the study also touches upon the role of ferritin, the iron storage protein, whose expression inversely correlates with IRP2 activity. Reduced ferritin levels ensuing from IRP2 inhibition lead to increased labile iron pools, further exacerbating mitochondrial oxidative stress. This iron-mediated toxicity culminates in heightened radiosensitivity, delineating an intricate balance where fine-tuning iron storage and utilization dictates cancer cell fate.

Crucially, the researchers employed advanced imaging and molecular biology techniques to verify their findings. High-resolution confocal microscopy, flow cytometry, and Western blot analyses collectively affirmed alterations in mitochondrial morphology, membrane potential, and expression of apoptotic markers post-IRP2 targeting. Such multi-modal approaches lend robust validity to the proposed mechanism, underscoring the therapeutic relevance of IRP2.

The implications extend beyond breast cancer, as aberrant iron metabolism and mitochondrial dysfunction are hallmarks observed in diverse malignancies. Thus, the therapeutic targeting of IRP2 may represent a broadly applicable strategy, potentially revolutionizing how radiosensitivity is modulated across cancer types and enhancing the universal efficacy of radiation therapy.

Importantly, safety profiles and specificity of potential IRP2 inhibitors remain critical considerations. Future research will necessitate rigorous preclinical and clinical evaluations to ascertain the selectivity of such compounds for cancer cells, minimizing off-target effects on normal tissues where iron regulation is equally vital. Balancing therapeutic gain against possible toxicities will be paramount in translating these findings into clinical reality.

The study also opens intriguing questions regarding the interplay between iron metabolism and other cancer survival pathways. For instance, how IRP2-related iron dysregulation interfaces with hypoxia-inducible factors, autophagy, and immune responses within the tumor microenvironment remains ripe for investigation. Clarifying these complex networks will unravel novel combinatorial treatment regimens that integrate metabolic targeting with conventional therapies.

Another avenue worthy of exploration lies in patient stratification. Identifying biomarkers that predict responsiveness to IRP2-targeted radiosensitization could optimize personalized treatment plans, ensuring that therapies are tailored to exploit specific metabolic vulnerabilities in tumor cells. Such precision medicine approaches promise improved therapeutic indices and patient quality of life.

In summary, the intricate study on IRP2 presents a transformative perspective on cancer therapy by coupling iron metabolism disruption with mitochondrial dysfunction to overcome radioresistance. It marks a pivotal step in the ongoing efforts to unveil metabolic Achilles’ heels within cancer cells. As investigative efforts continue, the integration of metabolic insights with traditional oncologic treatments holds the potential to redefine therapeutic standards, empowering clinicians with new tools to combat breast cancer’s formidable resilience.

Subject of Research: Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism and enhance radiosensitivity in breast cancer cells through mitochondrial dysfunction.

Article Title: Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism enhances radiosensitivity through mitochondrial dysfunction in breast cancer cells.

Article References:
Jeong, Y.Y., Hwang, J., Park, A. et al. Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism enhances radiosensitivity through mitochondrial dysfunction in breast cancer cells. Cell Death Discov. 11, 357 (2025). https://doi.org/10.1038/s41420-025-02653-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02653-z